AI is revolutionising brain surgery procedures鈥攖he technology isn’t replacing the skilled hands of a surgeon, of course, but it is certainly enhancing and assisting medical professionals greatly. AI algorithms have guided surgeons as they can now map out the brain with extreme precision before they even make their first incision.
 

AI: Early Detection and Proactive Treatment

 
The brain is an intricate organ, and often, the most lethal complications are the ones that go undetected at first. AI is stepping in to change this narrative by leveraging machine learning algorithms. AI can analyse medical images and detect anomalies such as tumours or blood clots that might be missed by human diagnosis. This allows for early intervention, improving chances of successful treatment and recovery. UK-based company Ultromics is using AI to identify heart disease early, an approach that could soon be replicated in neurology.

In age where the main contributor of numerous neurological diseases is tied to genetic predispositions, AI’s role in genetic analysis and predictive modelling is becoming increasingly crucial. It helps identify individuals at risk even before the onset of symptoms, providing a window for early intervention and potential preventative measures.
 

AI in Personalised Treatment Plans

 
AI isn鈥檛 just transforming diagnosis鈥攊t’s also altering the way treatment plans are devised. Each patient is unique, and so is their brain. AI algorithms can analyse a patient鈥檚 medical history, genetic makeup and current health status to recommend personalised treatment plans. This approach significantly increases the chances of success and reduces the risk of side-effects.
 

The Post-operative Role of AI

 
AI鈥檚 role doesn’t end as soon as the surgery is completed鈥攊t continues to support healthcare providers and patients post-operation. AI predicts potential complications, allowing for timely intervention. It can also guide rehabilitation programmes, ensuring they are personalised and effective for each patient.

AI can also play a crucial role in monitoring and predicting patient recovery patterns. By continuously assessing patients’ health data post-surgery, AI can alert healthcare providers of any unusual patterns that may indicate a complication, thereby aiding in early detection and intervention.

While these advancements may not replace human touch and judgement, it certainly complements it, ensuring the best possible patient outcomes.

Medical organisations and technology companies are currently collaborating more and the priority should be on ensuring this technology is accessible, affordable, and benefits patients worldwide.
 

AI’s Ethical Considerations

 
The balance between AI and human judgement, data privacy, and equality of access are all questions being grappled with, yet the benefits AI brings to the table are undeniable and as we continue to train and develop the advancements of these systems, we move closer to a future where brain surgery, among other medical procedures, is safer, more precise, and more accessible than ever before.

The post How AI is Revolutionising Brain Surgery and Other Medical Practices appeared first on 91探花.

They aren’t just fancy pedometers鈥擳he latest wearables provide a comprehensive health dashboard on your wrist, constantly updating you about your physical condition. As we strive towards a healthier nation, these devices help us gain invaluable insights into our well-being, facilitating proactive healthcare decisions.
 

The Rise of Biochemical Sensing

 
One of the most exciting developments in wearable technology is the third wave of biochemical sensing. The notion might sound like it belongs in a science-fiction novel, but it’s rapidly becoming a reality. These advanced wearable systems continuously monitor health-relevant molecules – glucose, electrolytes, ethanol, cortisol, to name a few – non-invasively.

Unlike traditional methods that require invasive blood tests, these devices use biofluids such as sweat, tears, and saliva to offer vital health information. These non-invasive biofluids carry a wealth of physiological data, and researchers are racing to unlock their potential.
 

A Reliable Health Ally

 
With healthcare鈥檚 advancement in this new world, the role of wearable health monitoring devices cannot be underestimated. They are personal health companions that offer insights and data which were once only possible through medical examinations. Though we are at the cusp of a revolution with the potential of molecular monitoring using non-invasive biofluids.

Reliability is key in this sector, and while current smart watches can provide basic health tracking data, the accuracy required for medical purposes is a different ball game altogether. The development of molecular monitoring techniques promises to deliver this level of accuracy, provided the challenges of calibration and biofluid sampling can be overcome.

The post Wearable Health Devices: A Step into the Future appeared first on 91探花.

When I joined the NHS as an Ear, Nose and Throat surgeon, I had no idea I was treading a path that would eventually lead me from medicine to entrepreneurship. Fast forward a few years and, having founded to build a solution to the outdated communication tools in use across the NHS, my role has transformed beyond recognition.

From surgeon to startup founder, I鈥檝e learned a lot along the way; but it turns out, some of the biggest lessons I was taught as a doctor have helped me immeasurably as an entrepreneur, too.

By sharing the three most important lessons that have accompanied me across my career so far, I hope they might also help those taking the first steps into the world of healthtech innovation.

1. Find the root cause of the ailment you鈥檙e trying to treat

A crucial lesson for any doctor is that symptoms must never be taken at face value. Instead, you must get to the absolute root of the problem that needs addressing. For healthtech entrepreneurs, the same is true. When building a tech solution it鈥檚 crucial to fully examine and understand the full picture of the issue you鈥檙e trying to solve.

At Cinapsis, we鈥檝e found that speaking to end-users from day one is essential to help identify the frustrations our product needs to address. Armed with this knowledge, we鈥檝e been able to听 intuitively听 design and tailor our platform to ensure it successfully addresses clinicians鈥� nuanced needs.

2. Put people front and centre

Just as it鈥檚 important to fully examine a patient鈥檚 underlying symptoms, as a doctor it鈥檚 essential to take into account the individual before you. Every patient is different, which means their needs and treatment are also invariably unique.

For any new tech innovation to be successful, it鈥檚 just as important to prioritise the individual. This means considering your end-users鈥� needs and experience at every stage of product design. No matter how great a solution is, if it鈥檚 tricky to use, requires lengthy onboarding or doesn鈥檛 easily sync with existing processes or systems being used, it鈥檚 unlikely to be adopted long-term.

3. Collaboration and partnership are key

Working together with my NHS colleagues when treating patients is pivotal to ensuring they receive the right care at the right time. Similarly, working in close partnership with others has formed the foundation of our work at Cinapsis.

Not only is close collaboration within your own team vitally important to ensure everyone is aligned and working towards the same goals, building strong partnerships with your clients is also fundamental to success. At Cinapsis, we work closely with our NHS partners to ensure our platform is continually tailored and evolved to work effectively for the clinicians it鈥檚 designed to support.

鈥�

Although I may not have known it at the time, the lessons I was learning as a medic have undoubtedly helped me just as much as a healthtech entrepreneur. From investigating the details of a problem to putting people first and collaborating closely with others, these are by far the most important skills I think every healthtech founder should put into use.

The post Dr Owain Rhys Hughes: ‘3 vital lessons I鈥檝e learned as a healthtech founder’ appeared first on 91探花.

 
The BBC recently reported that more than six million people are waiting for routine operations in the UK. Pre-pandemic, the UK government aimed to offer those needing non-urgent surgery a procedure within 18 weeks. In 2018, it was reported that hospitals achieved this around 88 percent of the time, so – even before COVID-19 – many patients were waiting a significant amount of time for surgery. The COVID crisis has brought into sharp focus an issue that has developed over decades.
 

The burden of delay

 
For each person on a waiting list in the UK, there is nothing routine about their condition. Those waiting for a hip or ankle replacement can be in constant pain. Many are unable to walk, leading to issues around lack of social contact and independence. This can impact people鈥檚 ability to work and, therefore, support themselves and their family.

This is not to say that healthcare systems are not doing everything they can to reduce this burden. Surgery techniques have radically changed to deliver better healthcare outcomes, and doctors are constantly looking to speed recovery to avoid issues of bed blocking and increase the volume of elective operations.
 

Innovation breeds new solutions

 
Perhaps the biggest opportunity to address the challenges with capacity comes from medical technology (MedTech). The MedTech sector has seen substantial growth in recent years. Prior to the pandemic in 2019, the total annual revenue of the global MedTech industry stood at 拢370.9 billion. By 2025, the global medical devices industry is expected to reach a valuation of 拢440.5 billion, growing at an average of 5.4 percent per year.

Innovation has been accelerated by the pandemic. As COVID-19 challenged the traditional healthcare processes it forced healthcare systems to quickly implement new solutions, such as tele-consultations and the increased use of remote monitoring to manage patients. This helped demonstrate the transformative potential of technology to healthcare systems.

MedTech can have a significant impact driving transformation around how care is provided, enabling healthcare professionals to focus on the critical. For example, remote monitoring can provide doctors with alerts that inform them of patients鈥� vital signs, but healthcare professionals will still need to interpret these.
 

Faster recovery, more capacity

 
MedTech devices that empower patients鈥� faster recovery, such as those that reduce swelling after surgery, can better enable patients to manage their recovery at home. This will reduce the time spent in hospital and reduce bed blocking, freeing up extra capacity to perform more operations.

Sustained time in hospital can also increase risk of infection. According to the World Health Organisation, healthcare associated infections are the most frequent adverse event in healthcare delivery worldwide. 10 percent of patients in developing countries and seven percent in developed countries will acquire at least one healthcare associated infection during their time in hospital.
 

MedTech improving wellbeing

 
COVID-19 has turbo charged a trend in healthcare that was already manifesting. Hospital waiting lists for routine operations were growing before the pandemic, but the impact on the healthcare crisis has hastened the need to generate meaningful positive change. If any positive has come from the pandemic it is that change that would ordinarily have taken a decade has been implemented in weeks or months.

The challenge now is to create healthcare systems that can address not only current needs but future ones, and effectively manage the backlog of elective surgery. The MedTech industry has a critical part to play in delivering ingenious solutions that will help healthcare systems manage demand moving forward.

The post How MedTech Can Help Tackle The NHS Backlog appeared first on 91探花.

Everyone knows how difficult it can be to get a blood test through traditional methods, and it鈥檚 only getting harder. This means that many diseases and health conditions aren鈥檛 being detected early enough and people are missing out on vital treatment.

Compounded by the backlogs caused by COVID, the lack of access to blood tests for regular health screening is creating a ticking timebomb in public health.

People are taking control of their own health data听

My wife Kiran and I felt for a long time that the key to fighting dangerous diseases is to increase access to testing, as early detection of anything serious can reduce its health implications. We both had personal experiences of family members struggling to get blood tests through traditional methods, such as Kiran鈥檚 father who was refused a cholesterol check by his GP. It got us thinking that routine testing should be made more available to the public.听We went on to create PocDoc together in 2020 and were the first app-based COVID-19 screening service in the UK.听

We saw during the pandemic this huge shift to self-testing, as it was required to get on with our daily lives. One of the positive outcomes of this is that many people are now taking control of their own health and want to be able to have access to their own health data immediately.

Personal diagnostics will听reduce听pressure on the NHS in the wake of the pandemic听

HealthTech which encourages personal diagnostics can free up desperately needed clinical time for the NHS while also helping people to detect potential health issues earlier for a fraction of the price of lab testing, helping to avoid long and costly treatment down the line and improve health outcomes across the board.

Take cardiovascular disease as an example. Cardiovascular disease (CVD) is the biggest killer in the world 鈥� but unlike cancer, it is largely preventable.听CVD is a major issue for health and social care in the UK, placing a considerable financial burden on the NHS and wider society, with CVD-related healthcare costs alone in England amounting to an estimated 拢7.4 billion per year*.

We鈥檝e just announced that this Spring we鈥檒l be launching a world-first smartphone-based test for cardiovascular disease, allowing people to test themselves via a blood prick from anywhere and getting results in just six minutes through their smartphone instead of waiting days or weeks for the same result through a standard lab test.

We鈥檝e estimated that this technology could save the NHS millions per year from reduced staff costs, administrative savings, reduced pathology costs and improved health outcomes just for cardiovascular disease.

HealthTech innovation will continue to support the NHS听

Starting with cardiovascular disease this Spring, we will be continuing to release tests for major diseases which will allow anyone with a smartphone to test for them at home, including type 2 diabetes, female hormone imbalance, kidney and liver diseases and more in the near future.

Our hope and mission is that HealthTech, like PocDoc, can support the NHS and continue to combat health inequality and help people to take control of their own health.

The post How HealthTech Can Help Relieve Pressure On The NHS And Empower People To Take Control Of Their Own Health appeared first on 91探花.

Any discussion on digital technology investment must be prefaced with the type of investment that is provided.听 Funding is frequently earmarked as capital expenditure when what the NHS requires is operational expenditure (the funds for running and maintaining new systems and technology).

It鈥檚 like being given the money for a deposit on a house without being able to afford the monthly installments. Too often, a lump sum of capital is made available 鈥� but then organisations have only two weeks to submit a bid and hope they are successful. Moving forward, the investment process must factor in the reality of healthcare organisations and enable them to plan programmatically for longer-term resource allocation.

Ultimately, funds will need to be focussed on improving productivity and the quality of the patient experience. The main pressure point in healthcare is the actual treating of patients, and so a priority for investment, perhaps, should not be diagnostics and imaging, which has been discussed recently but rather speeding up patient flow from admission to treatment to discharge, including unplanned admissions through Ambulances and A&E.
 

At the heart of efforts to improve this process is the adoption of solutions that are interoperable. There must be safe and effective sharing of information between systems in a way that makes critical health data accessible and usable for all parties involved.

Crucially, we must ensure that healthcare professionals have access to the most up-to-date information about their patients so that they can make the best and most informed medical decisions at critical moments of care. As long as digital systems remain in silos, and vital patient information from other systems or organisations is unavailable, the effectiveness of any digital transformation efforts will be largely stymied.

Any plans to alleviate strain on the NHS in the long-term must also consider ways to reduce the need for hospitalisation (or the time patients need to spend in hospital) in the first place. Better understanding patients鈥� long-term health, and findings ways to monitor citizens鈥� health remotely more effectively, are critical steps to freeing up limited NHS resources.

Such efforts will need to be strengthened by more robust and widespread health data sharing practices, that can both help to enable safe care outside of the hospital setting and improve the efficiency and safety of care inside a hospital.听 This could involve improving the flow of patients through a hospital, reducing the number of delayed transfers of care into the community and sharing current medications and allergies at the point of care.

Investing in tech is important, but it cannot come at the expense of investing in the right people and the right skills. It鈥檚 important that talent accompanies the technology if we鈥檙e to truly help healthcare workers where they need it most. The biggest issue in the NHS right now is the shortage of staff, a strain that is set to worsen as the UK goes into winter. Therefore, there needs to be concerted, planned increases in spending so that workforce and digital transformation efforts can be planned for, and paid for, over the next five to ten years.

Written by David Hancock, Healthcare Executive Advisor at InterSystems

The post David Hancock: Why Interoperability In Healthcare Is Vital To Relieving Pressure On The NHS appeared first on 91探花.

Flu-ID – which is powered by AI and Machine Learning – is proven to detect deterioration in an older person鈥檚 condition from flu up to 30x faster than traditional methods, and reduces diagnosis time for the virus from days to minutes, enabling faster treatment. This ensures Carers and Nurses can treat flu earlier and, crucially, in older people鈥檚 own homes rather than having them hospitalised.
 

What is Cera鈥檚 Flu-ID system?

 
Cera鈥檚 Flu-ID system runs through the company鈥檚 central App. Each day Nurses and Carers collate an older person鈥檚 vital signs, such as their temperature, heart rate and blood pressure, as well as other health indicators such as their nutrition, daily activity and sleeping patterns, into the App during in-person home care visits.

Through first of its kind AI and Machine Learning software, Cera鈥檚 app monitors these data points and can detect any worsening in their condition due to flu symptoms 30x faster than traditional methods – reducing the diagnosis rate for flu from days to minutes. This means that the onset of flu can be detected and treated much earlier, and in an older person’s own home rather than a hospital or surgery.
 

What impact can Flu-ID have?

 
Cera provides more than 45,000 in-person home care visits each day throughout the UK, through its network of almost 10,000 Carers and Nurses. The company already manages 5,000 alerts each day for conditions such as diabetes, infections and viruses. By treating these conditions faster, and remotely, Cera prevents unnecessary hospitalisations and improves health outcomes for older people.

By empowering it鈥檚 Carers and Nurses with this technology, Cera can drastically reduce hospitalisations across its own community, whilst at the same time freeing up beds and capacity in local hospitals and surgeries throughout the country. Cera hopes this will contribute significantly in preventing the NHS from becoming overwhelmed by the combined threat of flu and COVID-19 over the next six months.
 

Why has Flu-ID been launched?

 
The announcement comes as a range of industry bodies, and independent research, suggests that flu season could overwhelm the NHS this winter in tandem with COVID-19. The Academy of Medical Sciences has projected up to 7,000 hospital admissions from flu every week through winter, and the potential for up to 60,000 deaths from the virus1.

Likewise, the Society for Acute Medicine has warned that routine services could stop for 鈥榮everal months鈥�2 as a result of the flu, and the UK鈥檚 Chief Scientific Adviser Sir Patrick Vallance has suggested that flu rates could reach twice their typical seasonal level this winter3. The British Medical Journal has also launched research which found that those contracting the flu and COVID-19 at the same time were twice as likely to die, than individuals who caught either virus in isolation4.

Commenting on the launch, Dr Ben Maruthappu, CEO of Cera and healthcare policy expert, said:

鈥淭he key to protecting the NHS this winter, whilst at the same time preventing unnecessary challenges among our older community, is to reduce hospitalisations through faster detection and treatment for flu. Every time an older individual is admitted to hospital with flu, they risk catching secondary illnesses including COVID-19, and we鈥檝e learnt from the pandemic that treatment at home, where possible, leads to better outcomes. By empowering our network through AI, Machine Learning and Digitalised technologies, we can support and protect our community through what promises to be a difficult winter for the health and social care sector.鈥�

Launched in November 2016, Cera is one of Europe鈥檚 fastest-growing companies and has already established itself as the UK鈥檚 second-largest provider of home care services. The company delivers more than 45,000 in-person healthcare visits each day throughout the UK, and has grown to almost 10,000 staff delivering services such as care, nursing, repeat prescriptions and telehealth.

The post Cera Launches Flu Tracker And Treatment System To Protect Older People and The NHS This Winter appeared first on 91探花.

The planned expansion follows Flow鈥檚 success in treating patients across the UK and EU for the past two years, with its unique headset that delivers gentle stimulation using the tDCS technique to combat depression. The investment round will enable the company to strengthen its offering to the European market, servicing patients in their native language, as well as preparing for US market entry.

The Swedish born med-tech company founded by clinical psychologist Daniel M氓nsson, and neuroscientist Erik Rehn has grown from humble beginnings to fill the treatment gap between medication and therapy, with its first solution – the Flow headset – being the only drug-free, at-home tDCS depression treatment of its kind to be medically approved.

Global investors have come together to support Flow鈥檚 endeavour to branch out internationally – a strong endorsement for the cutting edge treatment method. Led by听, CSS Group through听听and听, the round was also joined by Kirin Holdings through Kiring health innovation fund led by听, a top venture capital based in Japan,听鈥檚 HAX, as well as the leading San Francisco based patent firm听. The cross-continental participants will fuel Flow Neuroscience鈥檚 core mission to create innovative treatments for mental health disorders that have no side effects, are easily accessible and empower patients and clinicians.

Michael Rieger, Head Innovation Operations & Portfolio at CSS GroupCSS Group comments: 鈥淔low offers completely new ways of treating clinical depression by applying a technology that has not been available to the general public until now. CSS is investing in Flow so as to grant patients access to this therapy approach and thus to close a gap in the healthcare system.鈥�

Dr Patrick Griss, Executive Partner at Z眉hlke, adds: 鈥淲e look for truly disruptive technologies that drive positive change in the world and with Flow we鈥檝e found that. A treatment that addresses the negative side effects seen with antidepressants and that allows autonomy in how patients can treat their health conditions, is something we are passionate to develop further.鈥�

Further to this, the investment from Khosla Ventures, leading US venture capital firm, and Global Brain together with Kirin holdings, will enable Flow to expand its treatment to the US and APAC, funding clinical trials that will pave the way for market access to patients and clinicians.

Alexander Morgan, MD PhD, Partner at Khosla says: 鈥淲e are happy to see continued progress with Flow鈥檚 medication-free treatment for depression and to reaffirm our commitment to the next stages of global expansion together. Bringing this portable, self-managed treatment to US patients will create a scalable, accessible solution to support the millions of people living with depression.听 The Flow approach can be adjunctive to other forms of therapy and can be an option for those who have not responded to other forms of treatment. We believe everyone in the world should have access to personalized, data-driven therapies.听 Flow is also empowering to users, as it provides substantial convenience and privacy; people can use it at home at times of their own choosing.鈥�

Looking to the future, Flow aims to increase its reach and accessibility to ultimately cure and manage mental health disorders. By providing a digital and remote device, Flow is revolutionising scientific research into the effects of tDCS on depression as researchers can recruit more participants and run trials at a much greater pace, without reliance on in-clinic participation. This allows for scalable expansion globally through clinical trial validation and through the development of a similar solution for anxiety.

Daniel M氓nsson, clinical psychologist and co-founder of Flow Neuroscience, explains: 鈥淲ith accessibility at the forefront, we have a three-fold mission at Flow over the coming years; to advance our current treatment to be more patient-specific and to treat more people suffering from depression; To accelerate our collaboration with healthcare systems to provide alternative options for clinicians to prescribe and a complementary solution to reduce waiting times; And, to work in collaboration with researchers in the field of tDCS to validate further self-managed treatment solutions for a wider range of mental health disorders, such as anxiety.鈥�

The post Flow Neuroscience Receives Series A Funding To Make Self-Managed Medical Device Available Globally appeared first on 91探花.

When conceiving which diagnostics would go into MedWand, the MedWand team selected tools most commonly used in the specialty of family medicine, designed to make the job of primary care clinicians easier and healthcare more accessible.

M.听Samir听Qamar, M.D., CEO of MedWand, said:

“As we saw with the pandemic, sickness isn’t confined geographically- and healthcare shouldn’t be either. MedWand doesn’t just complete telemedicine by enabling virtual physical exams, it does much more. By allowing patients to receive medical exams from anywhere on Earth, MedWand reveals the very future of medical practice.”

MedWand represents the evolution of telemedicine; enabling a multi-diagnostic assessment with a single device that can be used anywhere in the world. At only the size of a computer mouse, MedWand allows clinicians to conduct physical exams remotely, through the real-time collection of multiple vital sign readings and key patient assessments.

Recently demonstrated at Arab Health 2021 in Dubai, MedWand debuted its latest software advancements, which provide a link between MedWand devices and existing Electronic Medical Record and Practice Management Software. Supporting single password sign-in, accepting externally scheduled appointments, and exchanging patient data with the EMR, 惭别诲奥补苍诲鈥檚 virtual care clinic software delivers the ultimate in video consultation and remote exam performance.听With clinically accurate and real-time monitoring and recording of patient’s key vitals and clinical assessment, data collected via a MedWand include core temperature, blood oxygen saturation, pulse rate, heart, lung and abdominal auscultations, electrocardiogram, high definition otoscopic, oropharynx, and dermatoscopic exam images.

Robert Rose, President & COO of MedWand, added:

鈥�Telehealth needs MedWand and MedWand redefines telehealth completely. With MedWand, telehealth becomes even more meaningful, more effective, and will even save lives. That鈥檚 a powerful mission and I鈥檓 thankful for the opportunity to be part of it.鈥�

Depending on the market and local regulatory clearances, the MedWand device can include a stethoscope (with filters for heart, lungs, and abdominals), an otoscope (for the ears), and a dermatoscope (for skin lesions)鈥攁s well as a thermometer, a pulse oximeter (for monitoring heart rate and blood oxygen levels), and an ECG.

MedWand anticipates FDA clearance later this year. To learn more about MedWand and stay up to date on the company鈥檚 progress visit and and .

The post The Future of TeleMedicine Includes Physical Exams Thanks to Award-Winning Start-up: MedWand appeared first on 91探花.

Our Criteria Includes:

• The quality of the product offered
• How they stand out in their niche
• How beneficial the product is/has been
• Experience of their team and staff

See The 91探花 Top 39 MedTech’s

Top 39 >>

Top 20 >>

Top 10 >>

Do You Have Any Questions?

Please contact us here

Do you need funding for your business or startup? 91探花 works with a panel of VCs and Angel Investors.听Enquire today >>听

The post ANNOUNCED!!! 91探花’s Top 39 UK MedTech Companies appeared first on 91探花.